News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Genetic markers being used to target oral hepatitis C drug

Please note embargo:

Pharmac_P540c

Genetic markers being used to target new oral hepatitis C drug

A person’s genetic makeup will be used to target a new funded oral treatment for hepatitis C patients from 1 September.

PHARMAC will begin funding boceprevir (Victrelis) from 1 September 2013 for certain patients with the chronic liver infection. Boceprevir will be funded when used as a triple therapy in combination with pegylated interferon with ribavirin.

PHARMAC Medical Director Dr Peter Moodie says many hepatitis C patients do not respond well to current treatments, but that this could improve with the addition of boceprevir.

“Clinical evidence shows that, given the genetic characteristics of a patient, a simple genetic test can fairly accurately predict how they might respond to treatment,” says Dr Moodie.

“There is a group who we know respond poorly to current treatment. They are the ones we think will benefit most from the addition of this new treatment.”

About 25-35% of patients with certain genes showed a sustained response to the currently available treatment of pegylated interferon and ribavirin. By adding boceprevir to the treatment of these patients, the response rate increases to 70–75%.

As well as adding greater effectiveness to available treatments, Dr Moodie says boceprevir is the first funded oral treatment specifically for hepatitis C.

Patients will be genetically tested to determine whether they qualify for boceprevir (in combination with pegylated interferon and ribavirin) as a first-line treatment.

Boceprevir will also be funded for people who have tried but not responded completely to a course of pegylated interferon and ribavirin.

Dr Moodie says though many people live with hepatitis C without ever knowing it, the infection can cause significant health issues including hepatocellular carcinoma, liver failure, which may require a liver transplant.

Pharmacological treatment aims to reduce the likelihood of these transplants being required. In total, PHARMAC expects around 300 patients to start triple therapy in the next year.

In addition to funding boceprevir, PHARMAC has negotiated a price reduction for the Pegasys brand of pegylated interferon with ribavirin. Together, the funding of these hepatitis C treatments will cost $17.8 million over five years, with some of this cost being refunded through confidential rebates negotiated with both suppliers.

ENDS


© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Cyclists Net First NZ Gold

New Zealand won a gold meal and two bronzes on the first day of the Commonwealth Games. There was joy and heartbreak in an incredibly full day of sport. Here's how the New Zealanders fared. More>>

Cap Bocage: Anti-Mining Campaign Doco Debuts At NZ Film Festival

Playing at this year’s New Zealand International Film Festival, Cap Bocage is a close-up exploration of the forces that came into play when environmental issues and indigenous rights became intertwined in New Caledonia ... More>>

Film Fest:

More Film:

Sharon Ellis Review: A View From The Bridge

Arthur Miller’s A View From the Bridge is Circa’s latest big production, it opened on Saturday 19 July and it is a stunning triumph. More>>

Māori Language Week: He Karanga Kia Kaha Ake Te Tīhau Ki Te Reo Māori

The Māori Language Commission wishes to see social media swamped with Māori language tweets and messages for Te Wiki o te Reo Māori using the hashtag #tekupu. More>>

ALSO:

Book Vote: Kiwis Prefer Young Adult & Classics

To compile their Top 100 List for 2014, Whitcoulls again asked New Zealanders to vote for their favourite books and authors. And while classic novels continue to appeal to Kiwi readers, 2014 marks a significant new trend – the increasing popularity of novels for young adults. More>>

ALSO:

Five NZ Cities: Bill Bailey Back To The Southern Hemisphere

The gap between how we imagine our lives to be and how they really are is the subject of Bill’s new show Limboland. With his trademark intelligence and sharp wit, he tells tales of finding himself in this halfway place. More>>

Scoop Review Of Books: Book Television Is Coming

Carole Beu of The Women’s Bookshop in Auckland, Graham Beattie of The Book Blog and producer Deb Faith of FaceTV have raised enough money via crowd funding at Boosted – just under $7,000 so far – for 12 episodes, which begin production in September, and will be on screen later that month. More>>

Electric Sheep: Light Nelson Exceeds All Expectations

Light Nelson exceeded all expectations drawing over 40,000 people over two nights to the Queens Gardens and surrounds. The event, with over 40 installations from local and national artists, is in its second year, and organisers were hoping they’d top last year’s crowd of 16,000. More>>

MacGyver: Richard Dean Anderson To Attend Armageddon This October

New Zealand’s biggest pulp-culture event, the Armageddon Expo is proud to announce the world’s most recognised DIY action hero will be attending the Auckland event at the ASB Showgrounds from October 24th to 27th. More>>

ALSO:

Barbershop Gold: Māori Party Singing Praises Of The Musical Island Boys

The Maori Party has congratulated four young men on a mission, who in 2002 took up barbershop singing at Tawa College, and tonight took out the Gold Medal in the 2014 International Barbershop Harmony Society competitions in Las Vegas. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news